Association of fat mass profile with natriuretic peptide receptor alpha in subcutaneous adipose tissue of medication-free healthy men: A cross-sectional study

Introduction

Atrial natriuretic peptide (ANP) lowers arterial pressure to maintain fluid volume homeostasis, thus protecting against renal and cardiac pathogenesis¹. ANP also increases lipolysis in human adipocytes² by binding to natriuretic peptide receptor-A (NPRA)³. NPRA is less expressed in subcutaneous adipose tissue (SAT) in obese individuals and type 2 diabetes patients than in normal glucose tolerant individuals⁴. Also, NPRA signalling in skeletal muscle may enhance long-term insulin sensitivity⁵. Collectively, NPRA may potentially treat obesity-related disorders while ANP may play a role in the therapeutic mechanisms of beta-adrenoceptor antagonists in the mitigation of heart dysfunction and utilization of lipid mobilization⁶. However, the role of ANP in lipolysis has been primarily investigated mainly in vitro models^7–9, in human blood cells from individuals under medication treatment¹⁰, and in animal models⁹. To our knowledge, no such information is currently available in relation to the role of its receptor (NPRA) on the adipocytes of healthy individuals. Therefore, the aim of the current study was to examine the associations of NPRA mRNA of SAT with fat mass, fat-free mass (FFM), body mass index (BMI) and arterial blood pressure (BP) in medication-free healthy men.

Methods

The study was approved by the Ethics Committee of the University of Thessaly (protocol no. 698/2013). The inclusion criteria were: healthy adult men, non-smokers, no chronic disease and/or being under medication treatment. The participants were recruited by advertisements in a local newspaper in Trikala, Thessaly, Greece and the data collection started in July 2013 and ended in June 2014. Written consent was obtained from the 32 healthy men recruited [age (years): 36.06±7.36, BMI: 27.60±4.63 (kg/m²)].

To avoid misleading results, the participants refrained from exercise, alcohol, and passive smoking 72h prior the measurements, while they followed an overnight fast before they visit the physiology laboratory in the School of Exercise Science between 07:00–09:00 am. PCD and DP performed the following measurements: body height using a Seca 220 (Hamburg, Germany) stadiometer, body weight using a precision scale (KERN & Sohn GmbH, Version 5.3, Germany) and blood pressure using an Aneroid sphygmomanometer. Fat mass percentage (%FM) and FFM were measured via bioelectrical impedance using a body composition monitor (Fresenius Medical Care AG & Co. KGaA D-61346 Bad Hamburg, Germany).

Following the aforementioned measurements, the participants underwent a SAT biopsy in the physiology laboratory by a trained physician, as previously described¹¹. Briefly, the site of the incision was disinfected and a 10 ml of 2% xylocaine (no adrenaline) was injected for local anaesthesia. An incision of 2–2.5 cm was made 3–5 cm to the left of the navel. Nearly 500 mg of subcutaneous adipose tissue was captured and removed. The NPRA mRNA analysis of SAT samples is described elsewhere¹². Briefly, total RNA was extracted using RNeasy Lipid Tissue mini kit (QIAGEN). First-strand cDNAs were synthesized from equal amounts of total RNA using random primers and M-MLV reverse transcriptase (Promega). Quantitative real-time polymerase chain reaction was performed using Sybr Green fluorophore. 18S rRNA gene was used as a reference for normalization.

Following previous methodology, we removed two mean values (i.e. outliers) of NPRA mRNA that were at a distance of more than two standard deviations from the mean of the distribution^13,14. Also, there were three missing values in the NPRA mRNA analysis of SAT samples due to failure to extract RNA from adipose tissue. Eventually, 27 NPRA mRNA values were included in the statistical analysis using SPSS (version 24; SPSS Inc., Chicago, IL, USA). Normal distribution was determined using Shapiro-Wilk test, whereas Pearson’s correlation coefficient, linear regression, and Cohen’s f² effect size (R²/1-R²)¹⁵ were used to detect associations between NPRA mRNA, %FM, FFM (kg), BMI, and BP. We also used one-way analysis of variance (ANOVA) with Bonferroni post-hoc tests, and Cohen’s d effect size analyses to explore the mean differences of NPRA mRNA across different BMI categories [normal weight <25 kg/m² (n=9); overweight 25–30 kg/m² (n=9); obese >30 kg/m² (n=9)]. The level of significance was set at p≤0.05.

Results

The participants’ characteristics are provided in Table 1. The NPRA mRNA was negatively correlated with %FM (r=-0.40, p=0.03) (Figure 1) and BMI (r=-0.45, p=0.01) (Figure 2). No associations were found between NPRA mRNA and FFM, systolic or diastolic BP (p>0.05).

Linear regression analyses confirmed the associations between NPRA mRNA and %FM (R²=0.16, p=0.03) as well as BMI (R²=0.20, p=0.01). Cohen’s f² effect size analyses showed a small effect size between NPRA mRNA and BMI (f²=0.25), however, no effect size was detected between NPRA mRNA and %FM (f²<0.20). ANOVA demonstrated a strong tendency for mean differences in NPRA mRNA across BMI categories (p=0.06). This was confirmed by Cohen’s d effect size analyses in NPRA mRNA, revealing large effect sizes between obese individuals (BMI≥30 kg/m²) and either normal weight (BMI <25 kg/m²; d=0.94) or overweight (BMI=25–30 kg/m²; d=1.12) individuals.

Figure 1. Association of NPRA mRNA with fat mass %.

Figure 2. Association of NPRA mRNA with body mass index.

Discussion and conclusions

We have shown that the NPRA mRNA is negatively associated with %FM and BMI in medication-free healthy men and that it is expressed less in obese compared to lean individuals. Previous evidence showed that NPRA mRNA is expressed less in normal glucose tolerant individuals than in type 2 diabetes patients⁴, while it is positively associated with insulin sensitivity⁴. Given that insulin sensitivity is negatively associated with excessive FM in humans^16,17 the inverse association of NPRA mRNA with %FM and BMI observed in the current study suggests a possible role of NPRA in lowering FM in humans. Indeed, it has been established that natriuretic peptides by binding to NPRA, increase cyclic guanosine monophosphate – a well-known intracellular second messenger – which phosphorylates protein kinase G leading to activation of hormone sensitive lipase^18,19. This process mediates triglyceride degradation (i.e. lipolysis), which subsequently increases fatty acid availability¹⁸. Furthermore, findings in mice showed that the lack of NPRA gene may increase FM⁹.

The current study may be affected by methodological limitations such as the lack of insulin sensitivity measurements and a priori power calculation to determine the sample size. However, a post-measurements power calculation was conducted using an online software (DSS Research) to test statistical power. This revealed 89% of statistical power for the 27 available samples, based on the NPRA mRNA value (1.02±0.38) we detected in our study and expected NPRA mRNA value (0.81±0.08) from a previous similar study that examined NPRA in SAT in humans⁴.

In conclusion, NPRA mRNA is negatively associated with %FM and BMI in medication-free healthy men, suggesting a possible role of ANP/NPRA axis in the control of FM accumulation. To date, the investigation of NPRA has mainly focused either on circulating and muscle NPRA^20–22 or on medication-dependent NPRA measurements^4,10. Our study indicates that NPRA may also play role in FM profile of healthy individuals, which should be further explored in a cause-and-effect research setting.

Data availability

Dataset 1: Subcutaneous adipose tissue NPRA mRNA of medication-free healthy men 10.5256/f1000research.14198.d197694²³

BMI=Body mass index; SBP=Systolic blood pressure; DBP=Diastolic blood pressure; FFM=Fat-free mass; NPRA= Natriuretic peptide receptor-A.

BMI categories= 1. <25 kg/m², 2. 25–30 kg/m², 3. >30 kg/m².